Table 2 Subgroup analysis data
From: Efficacy of transversus abdominis plane block for gastric surgery: a meta-analysis
Outcome | group | Subgroup | No of study | Heterogeneity | SMD/WMD(95%CI) | P | |
|---|---|---|---|---|---|---|---|
I2(%) | P | ||||||
Pain Scores at 3 h postoperatively | Type of operation | LSG | 2 | 0 | 0.715 | -1.06 (-1.32, -0.79) | 0.000 |
Open radical gastrectomy | 2 | 53.4 | 0.143 | -0.74 (-1.18, -0.30) | 0.001 | ||
Pain Scores at 6 h postoperatively | Type of operation | LSG | 5 | 65 | 0.022 | -1.07 (-1.54, -0.59) | 0.000 |
Open radical gastrectomy | 4 | 64.6 | 0.037 | -0.85 (-1.28, -0.41) | 0.000 | ||
Injection method | Ultrasound guided | 8 | 68.3 | 0.002 | -0.96 (-1.29, -0.62) | 0.000 | |
Laparoscopically | 1 | N/A | N/A | -1.00 (-1.76, -0.24) | 0.010 | ||
Control group | Active placebo(Opioid) | 1 | N/A | N/A | -1.50 (-2.71, -0.29) | 0.015 | |
Active placebo(NSAIDS) | 1 | N/A | N/A | -0.10 (-0.89, 0.69) | 0.803 | ||
Placebo | 7 | 60.6 | 0.018 | -1.03 (-1.33, -0.74) | 0.000 | ||
Pain Scores at 12 h postoperatively | Type of operation | LSG | 5 | 84.1 | 0.000 | -1.02 (-1.60, -0.43) | 0.001 |
Open radical gastrectomy | 2 | 28.7 | 0.236 | -0.84 (-1.22, -0.46) | 0.000 | ||
Injection method | Ultrasound guided | 6 | 81.6 | 0.000 | -0.90 (-1.37, -0.42) | 0.000 | |
Laparoscopically | 1 | 78.9 | 0.000 | -1.30 (-1.80, -0.80) | 0.000 | ||
Control group | Active placebo(Opioid) | 1 | N/A | N/A | -0.90 (-1.96, 0.16) | 0.095 | |
Active placebo(NSAIDS) | 1 | N/A | N/A | 0.00 (-0.50, 0.50) | 1.000 | ||
Placebo | 5 | 56.6 | 0.056 | -1.16 (-1.47, -0.86) | 0.000 | ||
Pain Scores at 24 h postoperatively | Type of operation | LSG | 5 | 10.0 | 0.349 | -1.25 (-1.49, -1.00) | 0.000 |
Open radical gastrectomy | 5 | 0 | 0.834 | -0.38 (-0.58, -0.18) | 0.000 | ||
RYGB | 1 | N/A | N/A | -0.70 (-1.02, -0.38) | 0.000 | ||
Injection method | Ultrasound guided | 9 | 71.4 | 0.000 | -0.68 (-1.01, -0.35) | 0.000 | |
Laparoscopically | 2 | 85.4 | 0.009 | -1.08 (-1.86, -0.29) | 0.007 | ||
Control group | Active placebo(Opioid) | 1 | N/A | N/A | -1.00 (-2.06, 0.06) | 0.064 | |
Active placebo(NSAIDS) | 1 | N/A | N/A | -0.70 (-1.42, 0.02) | 0.056 | ||
Active placebo(PSI) | 1 | N/A | N/A | -0.70 (-1.02, -0.38) | 0.000 | ||
Placebo | 8 | 80.9 | 0.000 | -0.76 (-1.14, -0.37) | 0.000 | ||
Pain Scores at 48 h postoperatively | Type of operation | LSG | 2 | 76.8 | 0.038 | -1.36 (-1.85, -0.87) | 0.000 |
Open radical gastrectomy | 5 | 0 | 0.962 | -0.28 (-0.52, -0.05) | 0.017 | ||
Length of stay in hospital | Injection method | Ultrasound guided | 1 | N/A | N/A | 5.90 (0.41, 11.39) | 0.035 |
Laparoscopically | 3 | 89.0 | 0.000 | -6.35 (-21.20, 8.50) | 0.402 | ||
Control group | Active placebo(PSI) | 1 | N/A | N/A | -19.20 (-29.26, -9.14) | 0.000 | |
Placebo | 3 | 48.5 | 0.143 | 3.29 (-2.01, 8.59) | 0.224 | ||
Morphine consumption (SMD) | Type of operation | LSG | 1 | N/A | N/A | -2.09 (-2.61, -1.57) | 0.000 |
Open radical gastrectomy | 2 | 76.0 | 0.041 | -1.59 (-2.47, -0.72) | 0.000 | ||
LSG; LGB | 1 | N/A | N/A | -2.38 (-3.21, -1.55) | 0.000 | ||
Injection method | Ultrasound guided | 3 | 71.8 | 0.029 | -1.82 (-2.55, -1.09) | 0.000 | |
Laparoscopically | 1 | N/A | N/A | -2.09 (-2.61, -1.57) | 0.000 | ||
Control group | Active placebo(Opioid) | 1 | N/A | N/A | -2.09 (-2.61, -1.57) | 0.000 | |
Placebo | 3 | 71.8 | 0.029 | -1.82 (-2.55, -1.09) | 0.000 | ||
Time to first ambulation (SMD) | Injection method | Ultrasound guided | 1 | N/A | N/A | -0.53 (-1.05, -0.02) | 0.042 |
Laparoscopically | 2 | 85.5 | 0.009 | -0.44 (-1.15,0.27) | 0.224 | ||
Control group | Active placebo(Opioid) | 1 | N/A | N/A | -0.82 (-1.25, -0.39) | 0.000 | |
Placebo | 2 | 50.5 | 0.155 | -0.27 (-0.69, 0.16) | 0.218 | ||
Time to first flatus | Type of operation | LSG | 1 | N/A | N/A | -6.00 (-10.80, -1.20) | 0.014 |
Open radical gastrectomy | 2 | 0.0 | 0.743 | -4.33 (-9.16, 0.50) | 0.079 | ||
Injection method | Ultrasound guided | 2 | 0.0 | 0.743 | -4.33 (-9.16, 0.50) | 0.079 | |
Laparoscopically | 1 | N/A | N/A | -6.00 (-10.80, -1.20) | 0.014 | ||